Equity Details
Price & Market Data
Price: $1.79
Daily Change: +$0.0174 / 0.97%
Daily Range: $1.73 - $1.85
Market Cap: $537,490,816
Daily Volume: 976,806
Performance Metrics
1 Week: -7.29%
1 Month: -8.72%
3 Months: -11.44%
6 Months: -38.41%
1 Year: 137.3%
YTD: -20.54%
About ProKidney Corp. (PROK)
Access a quick overview of ProKidney Corp. (PROK). Trading at 1.79, the stock recorded a daily change of +$0.0174 / 0.97%. Its market cap is 537,490,816. Discover its performance over 3 months (-11.44%) and 6 months (-38.41%).
Company Details
Employees: 231
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.